Company intelligence / Profile preview

For-Robin, Inc.

Buffalo, New York, United Statesfor-robin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Preparing for IND for lung cancer imaging in collaboration with NCI NExT for 2024-2025 clinical imaging trials. The company's antibody can target all breast and lung cancer cell subtypes including triple negative breast cancer.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

3 assets

hJAA-F11

Pre-clinical

Indications: Triple negative breast cancer, Lung cancer

2 more assets in the full pipeline.

Request access →

Partnerships

National Cancer Institute's NExT programGoodwin BiotechnologyRoswell Park Comprehensive Cancer Center

Beyond the preview

Go deeper on For-Robin, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on For-Robin, Inc..

Explore the full profile